Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock
HOPKINTON, Mass., June 22, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today the pricing of its previously announced underwritten public offering of 2,884,615 shares of its common stock at a price to the public of $13.00 per share. Spring Bank’s gross proceeds from this offering are expected to be approximately $37.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Spring Bank has granted the underwriters a 30-day option to purc…
Read more